Primary biliary cirrhosis in adults

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 4, 2014, Pages 427-433

  Momah, Njideka ^a   Lindor, Keith D ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

adjunctive therapy; farnesoid X receptor agonist; obeticholic acid; primary biliary disease; ursodeoxycholic acid

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BEZAFIBRATE; BUDESONIDE; CENTROMERE ANTIBODY; CHENODEOXYCHOLIC ACID; CHLORAMBUCIL; COLCHICINE; COLESTYRAMINE; CYCLOSPORIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; METHOTREXATE; MITOCHONDRION ANTIBODY; MODAFINIL; MOEXIPRIL; NALTREXONE; NORFLUOXETINE; OBETICHOLIC ACID; ONDANSETRON; PLACEBO; PREDNISOLONE; RIFAMPICIN; RITUXIMAB; SILYMARIN; TAUROURSODEOXYCHOLIC ACID; TETRATHIOMOLYBDIC ACID; URSODEOXYCHOLIC ACID; 6-ETHYLCHENODEOXYCHOLIC ACID; CELL RECEPTOR; CHOLAGOGUE; FARNESOID X-ACTIVATED RECEPTOR;

ADJUVANT THERAPY; CHOLESTASIS; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEMOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LIVER BIOPSY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PREDICTIVE VALUE; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; PRURITUS; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; ADULT; AGONISTS; ANALOGS AND DERIVATIVES; AUTOIMMUNE DISEASES; IMMUNOLOGY; LIVER CIRRHOSIS, BILIARY;

ADULT; AUTOIMMUNE DISEASES; CHENODEOXYCHOLIC ACID; CHOLAGOGUES AND CHOLERETICS; HUMANS; LIVER CIRRHOSIS, BILIARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; URSODEOXYCHOLIC ACID;

EID: 84899024760     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.888950     Document Type: Review

References (84)

1. Addison T, Guys W. On a certain affection of the skin-vitiligoidea-a- plana f-tuberosa. Guys Hosp Rept 1851;7:265
2. Ahrens EH Jr, Kunkel H. The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis. J Clin Invest 1949;28(6 Pt 2):1565-74
3. Myszor M, James OF. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med 1990;75(276):377-85 (Pubitemid 20160082)
4. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119(6): 1631-6 (Pubitemid 32198688)
5. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56(5): 1181-8
6. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004;127(2): 485-92 (Pubitemid 39091897)
7. Zhang L, Weetman AP, Bassendine M, Oliveira DB. Major histocompatibility complex class-II alleles in primary biliary cirrhosis. Scand J Immunol 1994;39(1): 104-6 (Pubitemid 24232904)
8. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42(5):1194-202 (Pubitemid 43112687)
9. Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006;43(3):525-31
10. Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J 1980; 281(6243):772-5 (Pubitemid 10048546)
11. Prince MI, Chetwynd A, Diggle P, et al. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 2001;34(6):1083-8 (Pubitemid 33096579)
12. Leung PS, Park O, Tsuneyama K, et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 2007;179(4): 2651-7
13. Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5(11):1313-15 (Pubitemid 350019058)
14. Poupon R, Poupon RE, Calmus Y, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1(8537):834-6 (Pubitemid 17043131)
15. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128(2): 297-303 (Pubitemid 40431083)
16. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19(5):1149-56 (Pubitemid 24134236)
17. Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136(4):1281-7
18. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130(3):715-20 (Pubitemid 43374522)
19. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113(3):884-90 (Pubitemid 27381148)
20. Poupon RE, Bonnand AM, Chre'tien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999;29(6): 1668-71
21. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138(10):3525-31 (Pubitemid 17071942)
22. Lacerda MA, Shi XH, Zhang FC, et al. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995;90(2):247-9
23. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50(1):291-308
24. Kitami N, Ishii H, Shimizu H, et al. Immunoreactivity to M2 proteins in antimitochondrial antibody-negative patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1994;9(1):7-12 (Pubitemid 24041941)
25. Tsuneyama K, Van De Water J, Van Thiel D, et al. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. Hepatology 1995;22(5): 1440-6
26. Longo M, Crosignani A, Podda M. Hyperlipidemia in chronic cholestatic liver disease. Curr Treat Options Gastroenterol 2001;4(2):111-14
27. Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003;1(2):89-95 (Pubitemid 37248079)
28. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123(4): 1044-51
29. Levy C, Zein CO, Gomez J, et al. Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5(7):803-8 (Pubitemid 47031056)
30. Patanwala I, McMeekin P, Walters R, et al. A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score. J Hepatol 2013;59(2):327-35
31. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10(1):1-7 (Pubitemid 19169993)
32. Kim WR, Wiesner RH, Poterucha JJ, et al. Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transpl 2000;6(4):489-94 (Pubitemid 30489124)
33. Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005;42(3):386-92 (Pubitemid 40254254)
34. Rigopoulou EI, Dalekos GN. Anti-sp100 antibodies in primary biliary cirrhosis. Scand J Gastroenterol 2004;39(4): 406-7.author reply 407
35. Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004;2(12):1116-22 (Pubitemid 40037643)
36. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48(3): 871-7
37. Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011;55(6): 1361-7
38. Momah N, Silveira MG, Jorgensen R, et al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int 2012;32(5):790-5
39. Silveira MG, Brunt EM, Heathcote J, et al. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010;52(1): 349-59
40. National Environmental Policy Act of 1969, in U.S.C. 1994. p. 102-105
41. Jones DE, Bhala N, Burt J, et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006;55(4):536-41
42. Swain MG. Fatigue in chronic disease. Clin Sci (Lond) 2000;99(1):1-8 (Pubitemid 30479387)
43. Theal JJ, Toosi MN, Girlan L, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005; 41(6):1305-12 (Pubitemid 40770283)
44. Talwalkar JA, Donlinger JJ, Gossard AA, et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci 2006;51(11):1985-91 (Pubitemid 44832578)
45. Newton JL, Gibson GJ, Tomlinson M, et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006;44(1):91-8 (Pubitemid 44049142)
46. Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009;54(10):2242-6
47. Silveira M, Gossard AA, DeCook A, et al. Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis Hepatology. 2011;54(Suppl 4):1211A-2A
48. Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012;56(4):1391-400
49. Shoda M. Uber die ursodesoxycholsaure aus barengallen und ihre physiologische wirkung. J Biochem 1927;7:505-17
50. Iwasaki T. Uber die konstitution der urso-desoxycholsaure. Z Physiol Chem 1936;244:181-93
51. Cohen H, Alferiev IS, Mo?nkko?nen J, et al. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1- bisphosphonic acid betaine (ISA-13-1)- a novel bisphosphonate. Pharm Res 1999; 16(9):1399-406 (Pubitemid 29449377)
52. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 1994;204:1-15 (Pubitemid 24302605)
53. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237-67
54. Papastergiou V, Tsochatzis EA, Rodriquez-Peralvarez M, et al. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther 2013;38(11-12):1354-64
55. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013;144(3):560-9.e7; quiz e13-4
56. Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30(5):830-5 (Pubitemid 29248983)
57. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev 2004(2):CD004481
58. Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 2004;39(4):915-23 (Pubitemid 38428929)
59. Angulo P, Patel T, Jorgensen RA, et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;32(5):897-900
60. Charatcharoenwitthaya P, Talwalkar JA, Angulo P, et al. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci 2010;55(2):476-83
61. Silveira MG, Lindor KD. Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis? Transl Res 2010; 155(3):120-2
62. Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev 2007(3): CD006000
63. Li WX, Yan X, Shi CR, Zhang AP. Chlorambucil for patients with primary biliary cirrhosis. Cochrane Database Syst Rev 2012;9:CD008714
64. Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012; 55(2):512-21
65. Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database Syst Rev 2007(3): CD005526
66. Leuschner M, Gu?ldu?tuna S, You T, et al. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996;25(1): 49-57 (Pubitemid 26267092)
67. ClinicalTrials.gov identifier: NCT01829698. Available from: http://clinicaltrials.gov/ct2/ show/NCT01829698
68. ClinicalTrials.gov identifier: NCT01904058. Available from: http://clinicaltrials.gov/ct2/ show/NCT01904058
69. Devchand PR, Keller H, Peters JM, et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384(6604):39-43
70. Chianale J, Vollrath V, Wielandt AM, et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996;314(Pt 3):781-6 (Pubitemid 26097736)
71. Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011;33(2):235-42
72. Walker LJ, Newton J, Jones DE, Bassendine MF. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009;49(1):337-8. author reply 338
73. Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis 2012;13(4):219-24
74. Rautiainen H, Ka?rkka?inen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41(4):747-52 (Pubitemid 40462936)
75. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;31(2):318-23 (Pubitemid 30078594)
76. Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81(5):687-93
77. Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001;276(31):28857-65
78. Elfaki DA, Bjornsson E, Lindor KD. Review article: nuclear receptors and liver disease - current understanding and new therapeutic implications. Aliment Pharmacol Ther 2009;30(8):816-25
79. Fiorucci S, Clerici C, Antonelli E, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005; 313(2):604-12 (Pubitemid 40604160)
80. Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003:112(11):1678-87 (Pubitemid 38063725)
81. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45(17):3569-72 (Pubitemid 34856095)
82. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127(5):1497-512 (Pubitemid 39457775)
83. Mason A, Luketic V, Lindor K, et al. Farnesoid-x receptor agonists: a new class of drugs for the treatment of PBC? An International study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010;52(Suppl 1):S1-2
84. Hirschfield G, Kowdley K, Mason A, et al. Long-term (LT) therapy of a farnesoid X receptor (FXR) agonist obeticholic acid (OCA) maintains biochemical response in primary biliray cirrhosis (PBC). J Hepatol 2012;56(Suppl 2):S372